Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Stocks Yahoo Finance By Yahoo Finance 03 Jun 2026 18:00 1 min read

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Read the full story on Yahoo Finance → Opens the original article on finance.yahoo.com

Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.